AbbVie registers Phase 2b/3 study of ABBV-2294 in systemic sclerosis
The study plans to enroll 580 participants at about 200 sites worldwide, with a planned start date of December 11, 2026. It plans to evaluate the safety and efficacy of the combination of ABBV-722 and upadacitinib versus placebo over 52 weeks with optional extension periods.
Primary source
ClinicalTrials.gov registry record, November 12, 2026
A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.
Machine-summarized from the source above; not independently reported. How we use automation